LegoChem Biosciences and Amgen Enter into a
Multi-Target Research Collaboration and License Agreement for the Development
of Antibody-Drug Conjugates
· LCB Grants
Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates
Combining Targets Selected by Amgen with LCB’s Proprietary ADC Platform
· LCB Eligible
to receive up to $1.25 billion
LegoChem
Biosciences, Inc. (141080KS, ‘LCB’) announced on December xx that it has entered
into a research collaboration and license agreement with Amgen, whereby it
granted Amgen rights to research, develop, and commercialize ADCs directed
against up to 5 targets ed by Amgen based on LCB’s proprietary ConjuAll ADC
technology.
Under the terms of the agreement, LCB is eligible to receive up to $1.25 billion
including upfront, development and commercial milestone payments and is also eligible for tiered royalties as a percentage of worldwide
commercial sales by Amgen.
LCB’s clinical-stage
ConjuAll ADC technology platform provides optimized site-specific conjugation,
as well as cancer-ively activating linker and payload technologies for
ADCs. It overcomes the limitations associated with conventional technologies
that produce heterogeneous ADCs with its greater potency, safety and stability,
and enables the development ADCs with a wider therapeutic window and improved
manufacturability.
'Amgen has a
proven track record of bringing transformative medicines to market, and we are
pleased that they ed our ADC technology to integrate with their efforts
to develop next-generation ADCs,” said Yong-Zu Kim, LCB’s President and CEO.
“This licensing agreement demonstrates LCB’s continued recognition as an
industry-leading ADC player and further enhances our ability to innovate
through global partnership as we build out our pipeline and accelerate our
transformation into a fully-integrated oncology company.”
LCB has continued
to build a robust ADC licensing deal flow with 12 transactions completed with a
cumulative deal volume of over $5 billion.